奥泰生物: 关于2022年限制性股票激励计划首次授予第三个归属期及预留授予第二个归属期符合归属条件的公告

Core Viewpoint - The announcement details the fulfillment of vesting conditions for the third vesting period of the 2022 Restricted Stock Incentive Plan and the second vesting period for reserved grants, allowing a total of 438,890 shares to vest for eligible participants [1][14]. Group 1: Vesting Details - The total number of shares to vest is 438,890, with 409,472 shares from the first grant's third vesting period and 29,418 shares from the reserved grant's second vesting period [1][14]. - The shares are sourced from the company's repurchase of A-share common stock from the secondary market [1]. - The vesting conditions have been met for 94 eligible participants [1][14]. Group 2: Grant and Vesting Arrangements - The initial grant consisted of 770,000 shares (before adjustments), representing approximately 1.4285% of the company's total share capital of 53.904145 million shares [1]. - The vesting schedule includes three periods: 30% after 12 months, 30% after 24 months, and 40% after 36 months from the grant date [3][20]. - The reserved grant includes 50,000 shares, with a vesting condition of 50% after 12 months and another 50% after 24 months [3][20]. Group 3: Performance Assessment - The performance assessment for the incentive plan spans from 2022 to 2024, focusing on both company-level and individual-level performance metrics [5][20]. - Specific performance targets include revenue metrics and the number of approved self-developed products in domestic and international markets [5][20]. - The company-level vesting coefficient is calculated based on the achievement of set revenue and research targets, with a maximum of 100% if all targets are met [5][20].